Empowered Patient Podcast

Karen Jagoda
  • 4.9 (18)
  • 医学
  • 一日一更

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

  1. 17小时前 · 附赠内容

    Small Pediatric Practices Overcome Challenges of Vaccine Management with Pedro Sanchez de Lozada Canid TRANSCRIPT

    Pedro Sanchez de Lozada, CEO of Canid, highlights the significant financial risks that pediatricians face in managing their vaccine inventory.  There are administrative burdens associated with ordering, patient demand, tracking, reporting, and filing for insurance reimbursement. The Canid platform was designed to be a vaccine-as-a-service model, removing risk and administrative work from pediatric practices, allowing small and independent practices to achieve economies of scale, and freeing up more time to spend with patients and their parents.  Pedro explains, "When managing a vaccine program, the expectation is that the pediatrician will buy and maintain the stock in their office until a patient comes in and gets vaccinated. So, the refrigeration, the temperature logging, the stocking up, and the cost of the vaccine always fall as liability to the pediatrician. And what happens there is that you have a fairly small margin on these vaccines. Now I'm sure we're going to get into this, but when people say pediatricians make money on vaccines, they're usually cherry-picking." "But in reality, as a pediatrician, you actually have to stock all the vaccines. And not all of them have decent margins. Some of them have negative margins. And so as a portfolio, you end up making a pretty thin margin, and then that doesn't even include all the different challenges you might have along the way. So let's take an example: a vaccine that expires or is dropped, and unfortunately needs to be wasted."   "So the way that we like to think about it is we want to make it so that the pediatrician can just give vaccines. That's all they need to think about. And what that means is, let's just imagine for a second, a refrigerator that automatically restocks itself, and you just take out the vaccines, you give it to a child, and you go on your merry way. That's obviously a little bit of an idealistic way of viewing things, but it's the experience that we want to accomplish." #Canid #Vaccinations #Pediatricians #Vaccines #PediatricVaccineManagement   canid.io Listen to the podcast here

  2. 17小时前

    Small Pediatric Practices Overcome Challenges of Vaccine Management with Pedro Sanchez de Lozada Canid

    Pedro Sanchez de Lozada, CEO of Canid, highlights the significant financial risks that pediatricians face in managing their vaccine inventory.  There are administrative burdens associated with ordering, patient demand, tracking, reporting, and filing for insurance reimbursement. The Canid platform was designed to be a vaccine-as-a-service model, removing risk and administrative work from pediatric practices, allowing small and independent practices to achieve economies of scale, and freeing up more time to spend with patients and their parents.  Pedro explains, "When managing a vaccine program, the expectation is that the pediatrician will buy and maintain the stock in their office until a patient comes in and gets vaccinated. So, the refrigeration, the temperature logging, the stocking up, and the cost of the vaccine always fall as liability to the pediatrician. And what happens there is that you have a fairly small margin on these vaccines. Now I'm sure we're going to get into this, but when people say pediatricians make money on vaccines, they're usually cherry-picking." "But in reality, as a pediatrician, you actually have to stock all the vaccines. And not all of them have decent margins. Some of them have negative margins. And so as a portfolio, you end up making a pretty thin margin, and then that doesn't even include all the different challenges you might have along the way. So let's take an example: a vaccine that expires or is dropped, and unfortunately needs to be wasted."   "So the way that we like to think about it is we want to make it so that the pediatrician can just give vaccines. That's all they need to think about. And what that means is, let's just imagine for a second, a refrigerator that automatically restocks itself, and you just take out the vaccines, you give it to a child, and you go on your merry way. That's obviously a little bit of an idealistic way of viewing things, but it's the experience that we want to accomplish." #Canid #Vaccinations #Pediatricians #Vaccines #PediatricVaccineManagement   canid.io Download the transcript here

    24 分钟

  3. 1天前 · 附赠内容

    Accelerating Access to Cell and Gene Therapies with Alicia Silver ADVI Health TRANSCRIPT

    Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Listen to the podcast here

  4. 1天前

    Accelerating Access to Cell and Gene Therapies with Alicia Silver ADVI Health

    Alicia Silver, senior director at ADVI Health, highlights the evolving landscape of cell and gene therapy and the need to improve patient access and payment for these treatments. Availability of these therapies for solid tumors and genetic diseases like sickle cell disease is expanding due to the transition from inpatient to outpatient and community settings. The FDA's decision to remove REMS requirements for specific therapies has accelerated the growth of facilities to provide care, particularly for vulnerable populations. Alicia explains, "We work with a number of different cell and gene therapy clients throughout the sector. So we work with manufacturers who have commercialized cell and gene therapy products. So they have products that are currently on the market, manufacturers who are going through the process of clinical trials right now, working with the FDA to get approved products. But we also work with trade organizations that are working behind the scenes at the sector level, trying to get different policies and access changes for patients."   "To date, there's probably close to a couple of dozen FDA-approved cell and gene therapies, and they treat everything from blood cancers, which were the first approvals in something called CAR T. We saw blood cancers as the first approvals, and then everything through to solid tumors in oncology. But also, we have newer gene therapies for conditions like sickle cell disease. And that's an area that's been incredibly underserved and definitely will benefit from a durable gene therapy that hopefully corrects some of the issues that patients with sickle cell disease have, like pain crises that end up in a hospital. So from that perspective, we see a really wide range of treatments available to patients today and many more on the horizon." "I think the price tag is definitely somewhat of sticker shock for people who don't understand how cell and gene therapy products are valued. And so what we do a lot of times, educating on, is helping payers understand that it's not necessarily $2 million for a treatment that's going to be a recurrent payment, but something that's kind of an investment in the patient's and the plan's future." #ADVIHealth #CellTherapy #GeneTherapy #AcesstoCellGeneTherapy #ClinicalTrials  advi.com Download the transcript here

    21 分钟

  5. 2天前 · 附赠内容

    DNA-Based Immunotherapy Poised to Transform Ovarian Cancer Treatment with Dr. Stacy Lindborg IMUNON TRANSCRIPT

    Dr. Stacy Lindborg, President and CEO of IMUNON, has developed a DNA-based immunotherapy candidate for the treatment of ovarian cancer. This therapy works by administering the drug, which utilizes IL-12, a powerful anti-cancer cytokine, directly into the cavity where the cancer resides, thereby affecting the tumor microenvironment. Trials are showing that the drug can produce significant life extension when used in combination with standard chemotherapy. Stacy explains, "There are about 300,000 women who are newly diagnosed with advanced ovarian cancer every year, about 20,000 in the US, and the frontline standard of care hasn't seen a change in the treatment in about 25 years. So this is for newly diagnosed women. The very first treatment that they would have, which we call frontline treatment, is a platinum-based chemotherapy. So carboplatin and Paclitaxel are both administered through IV over an hour for carboplatin, about three hours for Paclitaxel. So most women go directly to chemotherapy and then surgery, and then chemotherapy. Some women will go straight to surgery and then have this chemotherapy afterwards."   "Our approach is a DNA-based immunotherapy candidate that we have in Phase 3. We refer to the lead candidate as IMNN-001, and this is a non-viral nanoparticle that is administered directly into the cavity of interest. So, what we call the micro-tumor environment is the peritoneal cavity, where the cancer actually resides, and it's delivered through a catheter. And it basically has a very powerful anti-cancer fighting cytokine, IL-12, that is encoded in this immunotherapy. And it causes the cells that are within each woman's body, both cancer and non-cancer alike, to start producing activities that will help fight these complex cancer cells that exist."  #IMUNON #OvarianCancer #DNABasedImmunotherapy #WomensHealth #CancerAwareness  imunon.com Listen to the podcast here

  6. 2天前

    DNA-Based Immunotherapy Poised to Transform Ovarian Cancer Treatment with Dr. Stacy Lindborg IMUNON

    Dr. Stacy Lindborg, President and CEO of IMUNON, has developed a DNA-based immunotherapy candidate for the treatment of ovarian cancer. This therapy works by administering the drug, which utilizes IL-12, a powerful anti-cancer cytokine, directly into the cavity where the cancer resides, thereby affecting the tumor microenvironment. Trials are showing that the drug can produce significant life extension when used in combination with standard chemotherapy. Stacy explains, "There are about 300,000 women who are newly diagnosed with advanced ovarian cancer every year, about 20,000 in the US, and the frontline standard of care hasn't seen a change in the treatment in about 25 years. So this is for newly diagnosed women. The very first treatment that they would have, which we call frontline treatment, is a platinum-based chemotherapy. So carboplatin and Paclitaxel are both administered through IV over an hour for carboplatin, about three hours for Paclitaxel. So most women go directly to chemotherapy and then surgery, and then chemotherapy. Some women will go straight to surgery and then have this chemotherapy afterwards."   "Our approach is a DNA-based immunotherapy candidate that we have in Phase 3. We refer to the lead candidate as IMNN-001, and this is a non-viral nanoparticle that is administered directly into the cavity of interest. So, what we call the micro-tumor environment is the peritoneal cavity, where the cancer actually resides, and it's delivered through a catheter. And it basically has a very powerful anti-cancer fighting cytokine, IL-12, that is encoded in this immunotherapy. And it causes the cells that are within each woman's body, both cancer and non-cancer alike, to start producing activities that will help fight these complex cancer cells that exist."  #IMUNON #OvarianCancer #DNABasedImmunotherapy #WomensHealth #CancerAwareness  imunon.com Download the transcript here

    21 分钟

  7. 3天前 · 附赠内容

    AI-Powered Movement-Based Medicine Platform with Donovan Campbell Medbridge TRANSCRIPT

    Donovan Campbell, CEO of Medbridge, empowers clinicians through a platform that is focused on movement-based medicine and a holistic approach to patient care. MedBridge has developed AI tools to perform triage, act as a care coordinator, and serve as a patient-facing coach, offloading administrative tasks and providing better support to patients. These tools are designed to support clinicians by flagging potential issues and increasing patient engagement by delivering immediate digital access to care.  Donovan explains, "We serve primarily physical therapists. And those physical therapists can work either in what's called a private practice outpatient setting or in a hospital setting, whether that's inpatient rehab or outpatient rehab. We also service physical therapy and adjacent practitioners, such as athletic trainers, speech and language pathologists, or occupational therapists. With the release of our new hybrid care platform, we're moving into different care categories, which is really exciting. So we're increasingly working with advanced primary care companies that service the employer health market. That's exciting. And we're exploring other opportunities within women's health and within orthopedics."   "Movement-based medicine is relevant to a really holistic approach to patient care, and it spans multiple clinical specialties. So think about the elderly patient who's just had a right knee replacement. Movement-based medicine is critical to getting them back up and on their feet. For a woman postpartum, pelvic health and movement-based medicine are really important. And pelvic health, movement-based medicine that she can access at home, is really important in her recovery and meeting her where she's at in her phase of life. And then physical therapy obviously is all about movement-based medicine."   #Medbridge #DigitalHealth #HealthcareAI #FutureAI #MovementBasedMedicine medbridge.com Listen to the podcast here

  8. 3天前

    AI-Powered Movement-Based Medicine Platform with Donovan Campbell Medbridge

    Donovan Campbell, CEO of Medbridge, empowers clinicians through a platform that is focused on movement-based medicine and a holistic approach to patient care. MedBridge has developed AI tools to perform triage, act as a care coordinator, and serve as a patient-facing coach, offloading administrative tasks and providing better support to patients. These tools are designed to support clinicians by flagging potential issues and increasing patient engagement by delivering immediate digital access to care.  Donovan explains, "We serve primarily physical therapists. And those physical therapists can work either in what's called a private practice outpatient setting or in a hospital setting, whether that's inpatient rehab or outpatient rehab. We also service physical therapy and adjacent practitioners, such as athletic trainers, speech and language pathologists, or occupational therapists. With the release of our new hybrid care platform, we're moving into different care categories, which is really exciting. So we're increasingly working with advanced primary care companies that service the employer health market. That's exciting. And we're exploring other opportunities within women's health and within orthopedics."   "Movement-based medicine is relevant to a really holistic approach to patient care, and it spans multiple clinical specialties. So think about the elderly patient who's just had a right knee replacement. Movement-based medicine is critical to getting them back up and on their feet. For a woman postpartum, pelvic health and movement-based medicine are really important. And pelvic health, movement-based medicine that she can access at home, is really important in her recovery and meeting her where she's at in her phase of life. And then physical therapy obviously is all about movement-based medicine."   #Medbridge #DigitalHealth #HealthcareAI #FutureAI #MovementBasedMedicine medbridge.com Download the transcript here

    21 分钟
查看全部 2,000 集

4.9
共 5 分
18 个评分

关于

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

信息

  • 创作者
    Karen Jagoda
  • 活跃年份
    2015年 - 2025年
  • 单集
    2000
  • 分级
    儿童适宜
  • 版权
    © 2024
  • 节目网站
    Empowered Patient Podcast

你可能还喜欢